Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs

Nanomedicines have gained popularity due to their potential therapeutic applications, especially cancer treatment. Targeted nanoparticles can deliver drugs directly to cancer cells and enable prolonged drug release, reducing off-target toxicity and increasing therapeutic efficacy. However, translati...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 14; no. 8; p. 1566
Main Authors Sabit, Hussein, Abdel-Hakeem, Mohamed, Shoala, Tahsin, Abdel-Ghany, Shaimaa, Abdel-Latif, Mokhtar Mamdouh, Almulhim, Jawaher, Mansy, Mohamed
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 28.07.2022
MDPI
Subjects
anticancer
Antimitotic agents
Antineoplastic agents
Cancer
Cancer therapies
Care and treatment
Dosage and administration
drug delivery
Drug delivery systems
Drug resistance
Drugs
Kinases
Nanomedicine
Pharmaceutical research
polymer nanocarriers
Review
Vascular endothelial growth factor
Vehicles
Egypt
Online AccessGet full text

Cover

More Information
Summary:Nanomedicines have gained popularity due to their potential therapeutic applications, especially cancer treatment. Targeted nanoparticles can deliver drugs directly to cancer cells and enable prolonged drug release, reducing off-target toxicity and increasing therapeutic efficacy. However, translating nanomedicines from preclinical to clinical settings has been difficult. Rapid advancements in nanotechnology promise to enhance cancer therapies. Nanomedicine offers advanced targeting and multifunctionality. Nanoparticles (NPs) have several uses nowadays. They have been studied as drug transporters, tumor gene delivery agents, and imaging contrast agents. Nanomaterials based on organic, inorganic, lipid, or glycan substances and synthetic polymers have been used to enhance cancer therapies. This review focuses on polymeric nanoparticle delivery strategies for anticancer nanomedicines.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14081566